About ampio pharmaceuticals inc - AMPE
Ampio Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and sexual dysfunction and CNS disease. The company was founded by David Bar-Or in December 2008 and is headquartered in Englewood, CO.
AMPE At a Glance
Ampio Pharmaceuticals, Inc.
9800 Mount Pyramid Court
Englewood, Colorado 80112
| Phone | 1-720-437-6500 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -8,632,000.00 | |
| Sector | Health Technology | Employees | 6 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
AMPE Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.508 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.232 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.127 |
AMPE Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,438,666.667 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
AMPE Liquidity
| Current Ratio | 2.357 |
| Quick Ratio | 2.357 |
| Cash Ratio | 1.721 |
AMPE Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -89.34 |
| Return on Equity | -113.961 |
| Return on Total Capital | -237.534 |
| Return on Invested Capital | -111.937 |
AMPE Capital Structure
| Total Debt to Total Equity | 8.155 |
| Total Debt to Total Capital | 7.54 |
| Total Debt to Total Assets | 4.777 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |